Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Apalutamide by Johnson & Johnson for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Apalutamide by Johnson & Johnson for Salivary Gland Cancer: Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Salivary Gland Cancer. According to...
Apalutamide by Johnson & Johnson for Prostate Cancer: Likelihood of Approval
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData,...